Danish pharma giant Novo Nordisk teased promising early-phase trial outcomes of its experimental weight loss capsule amycretin, sending the corporate’s stock surging.Some wellbeing programs address Zepbound for weight loss, but protection and copay amounts fluctuate. Strategies can also call for prior authorization prior to approving protection.